Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	All Solid Tumour	Advanced recurrent	TAPISTRY Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	Dr Tira Tan	NCT04589845	Open
2	All solid tumours	Advanced	BAYER 21820 First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors	Dr Tira Tan	NCT05537740	Open
3	NSCLC lung, PDAC / pancreatic and GC (GI)	Advanced recurrent	EBC-129-01 A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours	Dr Matthew Ng	NCT05701527	Open
4	NSCLC / lung, all solid tumours	locally advanced or metastatic / stage 4 / stage IV	NVL-520-01 A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)	Dr Daniel Tan	NCT05118789	Open
5	NSCLC / lung, all solid tumours	Advanced recurrent	NVL-655-01 A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Dr Aaron Tan	NCT05384626	Open
6	Pancreatic / GI	Advanced, Metastatic / stage 4 / stage IV	PAUF-I A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer	Dr David Tai	NCT05141149	Open
7	Breast	Advanced, Metastatic / stage 4 / stage IV	CAAA603D12101 A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor	Dr Yap Yoon Sim	NCT06247995	Open
8	Ovarian, lung, breast, endometrial	Advanced, Metastatic / stage 4 / stage IV	PMV-586-101 A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)	Dr Tira Tan	NCT04585750	Open
9	Ovarian, Endometrial and Lung adenocarcinoma	Advanced, Metastatic / stage 4 / stage IV	ZWI-ZW191-101 A Phase 1, Open-label, Multicenter, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of a Novel Folate Receptor Alpha Inhibitor, ZW191, as Monotherapy in Participants with Advanced Solid Tumors	Dr Daniel Tan	NCT06555744	Open
10	Squamous Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer	Advanced, Metastatic / stage 4 / stage IV	ALE.P02.01 A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with selected CLDN1+ solid tumors	Dr Darren Lim	NCT06747585	Open
11	all solid tumours	Advanced, Metastatic / stage 4 / stage IV	BAYER 22931 A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.	Dr David Tai	NCT06914128	Open
12	SCLC / Lung	Extensive-stage Small Cell Lung Cancer	CAAA601A42101 A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase	Dr Aaron Tan	NCT05142696	Open
13	Lymphoma	Advanced, Metastatic / stage 4 / stage IV	BCV-NL01 A Phase 1b/2, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and its Efficacy in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma	Dr Jason Chan	NCT06761677	Open
14	CRC, PDAC, NSCLC, other solid tumours	Advanced, Metastatic / stage 4 / stage IV	GO45416 A PHASE I/II DOSE-ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-7035 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A KRAS G12D MUTATION	Dr David Tai	NCT06619587	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Pancreas / GI/ BTC	Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	Open
2	Bladder / GU	Metastatic	SGNDV-001 An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)	Dr Ravindran Kanesvaran	NCT05911295	Open
3	Bladder / GU	Locally advanced or metastatic	BT8009-230 A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Dr Tan Wei Chong	NCT06225596	On hold
4	Breast	Mets ER+PR+	LaPemERLA Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study	Dr Yap Yoon Sim	NCT05286437	Open
5	Breast	Mets ER+PR+	ELEVATE A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors	Dr Elaine Lim	NCT05181033	Open
6	Breast	Mets HER2+/ PIK3CA mutant	INAVO122: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo versus Placebo in Combination with Phesgo after First Line Induction Therapy in Participants with PIK3CA-mutated HER2-positive Locally Advanced or Metastatic Breast Cancer	Dr Yap Yoon Sim	NCT05894239	Open
7	Breast	Mets HER2-/HR+ 1L Hormone resistant	CO44657 A phase III randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with Estrogen Receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy	Dr Yap Yoon Sim	NCT06065748	Open
8	Breast	ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	J2J-MC-JZLH / EMBER-4 A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	Dr Yap Yoon Sim	NCT05514054	Open
9	Breast	early stage I-III TNBC with Residual disease	MK-2870-012 A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery	Dr Rebecca Dent	NCT06393374	Open
10	Endometrial	recurrent / persistent endometrial cancer	GS-US-682-6769/ASCENT-GYN-01 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy	Dr Jack Chan	NCT06486441	Open
11	Endometrial	MMR proficient	MK2870-033 A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033)	Dr Jack Chan	NCT06952504	Open
12	Gastric GEJ / GI	Advanced 2nd and 3rd line	ASPEN-06 A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma	Dr Matthew Ng	NCT05002127	On hold
13	Gastric GEJ / GI	2L/3L Adv/Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	Open
14	Liver cancer or Colorectal cancer with liver metastases / GI	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
15	Liver / GI	Locally advanced	AHCC09 A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05377034	Open
16	Liver / GI	Resectable HCC (high risk of recurrence)	AHCC12 Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)	Dr Toh Han Chong	NCT05516628	Open
17	NSCLC / Lung	Mets NSCLC	BI 1479-0008 (BEAMION LUNG-02) A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations	Dr Stephanie Saw	NCT06151574	Open
18	NSCLC / Lung	Mets NSCLC	HMBD-001-103 A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers	Dr Aaron Tan	NCT05910827	Open
19	NSCLC / Lung	Locally advanced/ Mets NSCLC	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	Dr Stephanie Saw	NCT05261399	Open
20	SCLC / Lung	Limited-Stage Small-Cell Lung Cancer	20230016 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)	Dr Amit Jain	NCT06117774	Open
21	NSCLC / Lung	locally advanced / metastatic / Mets NSCLC, stage 4/ stage IV	TAS6417-301 An Open-Label, Randomized Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib (TAS6417) plus Pemetrexed and Cisplatin or Carboplatin, versus Pemetrexed and Cisplatin or Carboplatin, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations (REZILIENT3)	Dr Gillianne Lai	NCT05973773	Open
22	NSCLC / Lung	Mets NSCLC	LUNAR-2 EF-44 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer	Dr Ng Quan Sing	NCT06216301	Open
23	NSCLC / Lung	Advanced NSCLC	20230153 Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with methylthioadenosine phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)	Dr Darren Lim	NCT06593522	Open
24	NSCLC / Lung	II to IIIB (N2) NSCLC	V940-009 A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)	Dr Aaron Tan	NCT06623422	Open
25	NSCLC / Lung	Mets NSCLC	IOV-LUN-202 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145)in Patients with Metastatic Non-Small-Cell Lung Cancer	Dr Sophia Wong	NCT04614103	Open
26	NSCLC / Lung	Mets NSCLC	M25-274 A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Dr Gillianne Lai	NCT06568939	Open
27	NSCLC / Lung	Locally Advanced/ Mets NSCLC	D516KC00001 A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)	Dr Tan Wan Ling	NCT06417814	Open
28	Lymphoma	Relapsed/ Refractory B-cell lymphoma	MK2140-006 A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies	Dr Esther Chang	NCT05458297	Open
29	Lymphoma	relapsed/ refractory Lymphoma	POLAR Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)	Dr Lim Soon Thye	NCT06160843	Open
30	Lymphoma	relapsed/ refractory lymphoma	R1979-HM-2299 A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)	Dr Tertius Tuy	NCT06230224	Open
31	Lymphoma	untreated B-cell lymphoma	CA073-1020 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)	Dr Chandramouli	NCT06356129	Open
32	Lymphoma	relapsed/ refractory lymphoma	M22-128 A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Dr Chandramouli	NCT06508658	On hold
33	Lymphoma	untreated B-cell lymphoma	MK-2140-010 A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)	Dr Joshua Hoe	NCT06717347	On hold
34	Lymphoma	relapsed/ refractory follicular lymphoma	EZH-302 SYMPHONY-1 A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma	Dr Ong Shin Yeu	NCT04224493	On hold
35	NPC	Metastatic, mets	SG-AAA-II-01 / CAAA601A0SG01T A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in	Dr Daniel Tan	NCT05198479	Open
36	NPC	stage IIIA-IVA	RIBBON-LA-01 Single-arm, open-label, phase 2 trial of tislelizumab and metronomic capecitabine as maintenance therapy in high-risk locoregionally-advanced nasopharyngeal carcinoma	Dr Darren Lim	NCT06093061	Open
37	NPC	recurrent/metastatic	NRG-HN011 A randomized phase II study of nivolumab versus nivolumab and BMS-986016 (relatlimab) as maintenance treatment after first-line treatment with platinum-gemcitabine-nivolumab for patients with epstein-barr virus-associated recurrent/metastatic nasopharyngeal carcinoma (REMAIN)	Dr Darren Lim	NCT06029270	Open
38	Ovary, fallopian and pertioneal	advanced	TRIO057/TORL-1-23 (CATALINA-2) A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women with Advanced Platinum Resistant Epithelial Ovarian Cancer (including Primary Peritoneal and Fallopian tube cancers) expressing Claudin 6 (CLDN6)	Dr Chay Wen Yee	NCT06690775	Open
39	Pancreas / GI	Metastatic	LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients	Dr Joycelyn Lee	NCT05929885	Open
40	Pancreas / GI	Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	Open
41	Prostate	Metastatic	CAAA617D12302 An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)	Dr Jeffery Tuan	NCT05939414	Open
42	Prostate	Metastatic/ mCRPC	MK-5684-003 A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Dr Ravindran Kanesvaran	NCT06136624	On hold
43	Prostate	Metastatic/ mCRPC	MK5684-004 A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)	Dr Johan Chan	NCT06136650	Open
44	Prostate	Metastatic/ mCRPC	CAAA817A12201 A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus best standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy	Dr Ravindran Kanesvaran	NCT06780670	Open
45	Prostate	Metastatic/ mCRPC	AMG 20230005 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-Resistant Prostate Cancer	Dr Johan Chan	NCT06691984	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
2	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
3	SOLID TUMORS (currently only HCC and gastric cohorts are opened)	Advanced curatively unresectable solid tumors failing standard therapy. HCC: must have failed at least 1 line of standard therapy Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment) Other solid tumours: must have failed at least 1 line of standard therapy	NCCS-2018-Phase2-PRL3 An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours	Dr Matthew Ng	NCT04118114	Open
4	SOLID TUMORS	ADVANCED/ METASTATIC	Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations	Dr Joanne Ngeow	NCT04924075	Open